Bladder: Announcements

2024 Special Issue：Molecular Subtype Profiling of Urothelial Carcinoma

Bladder — 2024-03-26

Introduction of the Molecular Subtype Profiling of Urothelial Carcinoma Special Issue

Bladder: Molecular Subtype Profiling of Urothelial Carcinoma may include: investigations on the molecular events/mechanisms underlying urothelial carcinoma that typically starts in the urothelial cells lining the urinary tract, including, the bladder, ureters, and renal pelvis. In this issue, areas of interest include (but not limited to) molecular exploration of urothelial carcinoma by employing multiomic strategies such as, genomic, transcriptomic, epigenomic, proteomic, metabolomic techniques. Emphasis is placed on molecular subtyping in different ethnic and geographic populations, and work designed to translate the molecularly defined subtypes into better patient stratification and personalized management of urothelial malignancies.

Guest Editors-in-Chief Profile

Tianxin Lin

Dr. Tianxin Lin is a distinguished professor at Sun Yat-sen University. He is currently the President of The Fifth Affiliated Hospital of Sun Yat-sen University, the Vice President of Sun Yat-sen Memorial Hospital, the Director of the Hospital Management Department, the Deputy Director of the Health Science Center, and the Assistant Principal of Sun Yat-sen University. Prof. Lin is a recipient of National Science Fund for Distinguished Young Scholars, the Chief Scientist of National Key Research and Development Programs, and is now on the National Plan for the Special Support for Top-notch Talents. He is also serving as a standing member and secretary general of the Chinese Urological Association, the Vice President of Chinese Urological Doctor Association, and the Chairman of the Guangdong Urological Association. Prof. Lin has been working in the field of the precise diagnosis and treatment, basic research and translational medicine of urological cancer, especially bladder cancer. As the first author (including co-first) and corresponding author (including co-corresponding), Prof. Lin published over 170 papers in a wider array of prestigious journals, including Cell, Science, Lancet Oncology, Cancer Cell, European Urology, and Nature Biomedical Engineering, etc. For his outstanding accomplishments in the field of bladder cancer, Prof. Lin was awarded the National Award for Excellence in Innovation, the Ding Ying Science and Technology Award in Guangdong Province, the First Prize of Guangdong Science and Technology Progress Award, and the Wu Jieping Urological Surgery Medical Award, among others.

Chong Chen

Dr. Chong Chen is a professor in Sichuan University. Dr. Chen graduated from Peking University and University of Michigan-Ann Arbor and earned his BS and PhD degrees, respectively. After completing his postdoctoral program in Scott Lowe’s laboratory in Cold Spring Harbor Laboratory and Memorial Sloan Kettering Cancer Center, he joined the State Key Laboratory of Biotherapy, West China Hospital, Sichuan University in 2014. His research has been focusing on the molecular mechanisms driving cancer evolution. His laboratory has established a series of novel animal models of bladder, lung, gastric cancers, and other malignancies by using genetically-engineered premalignant organoids. They have identified multiple new tumor suppressors, including KMT2C, PHF23, and ALOX15B. They found a novel type of lineage plasticity, termed "semi-squamatization", a feature underlying acquired chemoresistance, and proposed a differentiation therapy for bladder cancer. Their work has been published in Nature, Nature Cancer, Cancer Cell, and Cancer Discovery. Dr. Chen received the 2022 WuXi AppTec Life Chemistry Research Award.

Accepted types of manuscripts:

1. Research review: An in-depthsumming upof representative research results in the field over the last 5 to 10 years and their implications, with an overall review of the status quo and future trends of the relevant field. The review should be based on or directly related to the work or field the authors are engaged in.

2. Researchpapers: The original research paper should cover the latest scientific research results, which are innovative and of theoretical and practical value, such as studies regarding basic research and core technological research in the field.

3. Mini reviews: Such reviews shouldoffer a brief and focused summary of recent insights or advances in genomics and precision medicine.

4. Perspectives: Expert views and opinions ontheissues important to genomics or precision medicine.

5. Research highlights: These include short commentaries on one or more recently published journal articles that reported novel and significant findings. Research highlights should be commissioned from leading experts in the field of genomics and precision medicine.

How to SUBMIT your paper:

Please click "Make a Submission" and choose "2024 SI: Molecular Subtype Profiling of Urothelial Carcinoma" in the article type section.

2023 Special Issue: Genomics and Precision Medicine

Bladder — 2023-04-28

Introduction of the Genomics and Precision Medicine special issue

Bladder: Genomics and Precision Medicine may include: investigations of the molecular basis underlying diseases such as cancer of the bladder and its neighboring organs. The scientific content would include genetic and genomic association studies and functional interpretation, epigenomics, transcriptomics, proteomics, metabolomics, and metagenomics as well as integration of electronic health record data or patient-derived data with any of the aforementioned approaches; systems biology approaches to the diagnosis and management of diseases of the bladder and urinary tract covering by urothelium; and novel applications of precision medicine.

Guest Editors-in-Chief Profile

Gong-Hong Wei

Dr. Gong-Hong Wei is currently a distinguished professor at Shanghai Medical College, Fudan University. Dr. Wei graduated from his PhD study in Peking Union Medical College, Beijing, China. After postdoctoral training at the University of Helsinki, Finland, Dr. Wei joined in the University of Oulu as a faculty member and then a full professor, heading a functional and systems genomics laboratory for cancer research. Dr. Wei’s laboratory focuses on the epigenetic regulation of gene expression network during cancer susceptibility, initiation and progression to metastasis, and the identification of biomarkers for cancer risk prediction and stratification. Over the past several years, Dr. Wei’s team performed systems functional interpretation of noncoding genomic variations in association with cancer discovered by genome-wide association studies and investigated cancer driver genes revealed by whole genome sequencing, and published several senior-authored papers in the international top journals such as Cell and Nature Genetics. Dr. Wei received a prestigious Academy of Finland Research Fellow post and title of docent (honorary title granted for lifetime) in molecular genetics in 2014, and was shortly promoted as a full professor, and recently joined Shanghai Medical College of Fudan University as a distinguished professor. Dr. Wei won the Medix Prize 2015 and 2019, and the Discovery of the Year 2014, 2016 and 2018 at Biocenter Oulu, and served as a reviewer for over 40 different journals, including Nature Genetics, Nature Communications, Genome Research, Cell Research, Cell Discovery, Science Bulletin and so forth.

Song Wu

Dr. Song Wu is currently a distinguished professor at Shenzhen University, deputy director of the Department of Medicine, president of South China Hospital, winner of the Guangdong Youth Science and Technology Award, Shenzhen Youth Science and Technology Award, the leading talent of Guangdong Science and Technology Innovation, and winner of the National May Day Labor Medal, mainly engaged in medical research such as the mechanism of urinary diseases, clinical diagnosis and treatment, and the construction of intelligent diagnosis system. He leads the key project of the National Natural Science Foundation of China (Department of Informatics), the Outstanding Youth Fund of the National Natural Science Foundation of China (Ministry of Medicine), the Ministry of Science and Technology Key Research and Development Special Project (Young Scientist Program), and other funds. As the first author (including co-one) and corresponding author (including co-author), he published 82 SCI papers in journals such as EUR UROL, ICASSP, EUR RADIOL, NAT GENET, ADV MATER, and CELL RES. Among them, 54 papers were published as the final communication or independent communication, 36 papers in JCR Region I, 21 papers in Region I of the Chinese Academy of Sciences, 16 papers IF> 10.0, 6 papers IF> 20.0, 4 papers IF>30.0, the total number of citations of Google Scholar is "5501", the H-index is "34", and the international level of professional fields is in the top "0.57%". He has transferred 4 patents, achieved 2 product development and marketing, obtained 2 national medical device certificates, and provided nearly 10 million screenings for non-invasive early screening products transformed into the urine. He has published 396 articles related to health management, with a cumulative total of 1.01 million views. He is the Chief Editor of Introduction to Precision Medicine and Saying Goodbye to Urinary Tract Stones. He serves as the editorial board member of the classic Chinese surgical treatise Wu Jieping Urology and Guidelines for the Diagnosis and Treatment of Bladder Cancer.

Accepted types of manuscripts:

1. Research review: An in-depth summary of representative research results in the field in the last 5 to 10 years, with a comprehensive review of the scientific significance, current research status and development trends in the field. The content of the review should be based on or directly related to the author's professional research.

2. Research papers: Report the latest scientific research results with theoretical, innovative and important scientific value, such as basic research and core technology research in the field.

3. Mini reviews: offer a brief and focused summary of recent insights or advances in genomics and precision medicine.

4. Perspectives: expert views and opinions on issues of importance to genomics or precision medicine.

5. Research highlights: short commentaries on one or more recently published journal articles that report novel and significant findings and interest the readers. Research highlights should be commissioned from leading experts in the field of genomics and precision medicine.

How to SUBMIT your paper:

Please click "Make a Submission" and choose "2023 SI: Genomics and Precision Medicine" in the article type section.